Comparative Pharmacology
Head-to-head clinical analysis: DUEXIS versus INDOMETHACIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUEXIS versus INDOMETHACIN.
DUEXIS vs INDOMETHACIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DUEXIS is a combination of ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, and famotidine, a histamine H2-receptor antagonist that decreases gastric acid secretion. Famotidine mitigates the risk of NSAID-induced gastric ulcers.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.
One tablet (800 mg ibuprofen/26.6 mg famotidine) orally three times daily.
25-50 mg orally 2-3 times daily; maximum 200 mg/day. Also available as 75 mg sustained-release capsule orally once daily, or 50 mg rectally 3-4 times daily.
None Documented
None Documented
Clinical Note
moderateIndomethacin + Gatifloxacin
"Indomethacin may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateIndomethacin + Rosoxacin
"Indomethacin may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateIndomethacin + Levofloxacin
"Indomethacin may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateIndomethacin + Trovafloxacin
Ibuprofen: 2-4 hours (terminal); requires every 6-8 hour dosing. Famotidine: 2.5-3.5 hours (normal renal function); prolonged to 20 hours or more in severe renal impairment (CrCl < 30 mL/min).
Terminal elimination half-life is approximately 4.5 hours (range 2.6-11.2 hours) in adults; prolonged in neonates (up to 17 hours) and in patients with renal impairment or cholestasis; clinical context: dosing interval adjustments needed in hepatic or renal disease.
Ibuprofen: ~1% unchanged in urine, 14% as conjugated metabolites, remainder as oxidative metabolites; <1% excreted in feces. Famotidine: 65-70% unchanged in urine, 30-35% metabolized hepatic; <10% fecal.
Renal excretion of unchanged drug and metabolites (approximately 60% as parent drug and glucuronide conjugate; 23% as O-desmethyl metabolite; 13% as glucuronide of O-desmethyl metabolite); biliary/fecal elimination accounts for 30-40%, primarily as glucuronide conjugates.
Category C
Category D/X
NSAID/H2 Antagonist Combination
NSAID
"Indomethacin may increase the neuroexcitatory activities of Trovafloxacin."